PET/MR Imaging In Patients With Cardiac Amyloidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

33 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-25

Study Completion Date

2020-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PET scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. It involves injecting a radioactive tracer which highlights abnormal areas. It has recently been combined with CT (computed tomography) and MRI (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. Cardiac amyloidosis, a condition which causes thickening of heart muscle due to abnormal protein deposits, is of particular interest. There are different forms of this condition and at present samples of tissue need to be taken and analysed in order to assess these accurately, which carries risks.

The study makes use of hybrid PET/MR scanning using a designated scanner which enables PET scanning combined with MRI scanning. The investigators will use a PET tracer which is widely used in cardiac imaging as it is hoped this will enable characterisation of abnormal areas within the heart in this condition in a way which hasn't been done before.

All participants will undergo PET scanning, where a radioactive tracer is injected into a vein before the scan. The radioactive substance only lasts for a short time and is safe, passed out of the body in urine. If successful, this imaging method will enable us to detect differences between different forms of cardiac amyloidosis in a non-invasive way, improving the diagnostic capabilities in this condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET/MR Imaging In Patients With Infective Endocarditis

NCT03626571

Infective Endocarditis

COMPLETED

Molecular Imaging of Primary Amyloid Cardiomyopathy

NCT02641145

Amyloidosis, Primary Cardiomyopathy

RECRUITING NA

PET-MR Imaging of Coronary Atherothrombosis

NCT03618303

Heart Diseases, Ischemic

COMPLETED NA

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

NCT05619302

Cardiac Amyloidosis

RECRUITING PHASE3

Angiogenesis and Fibrosis in Myocardial Infarction

NCT01813045

Myocardial Infarction Fibrosis Neovascularization, Pathologic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiac Amyloidosis Patients

Patients with established diagnosis of cardiac amyloidosis.

18F-NaF PET

Intervention Type OTHER

Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes

Healthy Volunteers

Healthy volunteer subjects of similar age and gender to patient cohort.

18F-NaF PET

Intervention Type OTHER

Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-NaF PET

Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged over 40 years
* Completion of informed consent
* Established diagnosis of cardiac amyloidosis

Exclusion Criteria

* Inability or unwilling to give informed consent
* Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.
* Major intercurrent illness with life-expectancy \<2 years.
* Renal dysfunction (eGFR less than or equal to 30ml/min/1.73m2)
* Adverse reaction or hypersensitivity to 18F-FDG PET tracer
* NYHA Class IV heart failure
* Patients with atrial fibrillation and poor rate control
* Contraindications to MRI scanning
* Previous history of contrast allergy of adverse reactions (Gadolinium-containing agents)

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes